In this retrospective study, we evaluated imaging data from 65 breast cancer patients that were obtained one to three days before the initiation of neoadjuvant chemotherapy (NAC). Imaging was performed with a dynamic optical tomography breast imaging system (DOTBIS) over the course of a breath hold. From this imaging data, we extracted time-dependent signal traces of the total hemoglobin in the whole volume of the tumor-bearing breast. The inflection point and the slope at the steepest part of the curve were calculated for both the ascending (patient holds her breath) and descending slopes (patient releases her breath and starts breathing normally again). Our results show statistically significant differences in vascular changes between patients with a pathologic complete response (pCR) and non-pCR patients. This suggests that differences in the tumor-bearing breasts of these two patient groups exist even before treatment is started.
This work evaluates changes in features of 3D breast images generated by a so-called dynamic optical tomographic imaging system (DOTBIS) during neoadjuvant chemotherapy (NAC). Images from 23 breast cancer patients were analyzes and correlated with respect to treatment outcome and status of hormone receptors and human epidermal growth factor receptors. Our data shows that the ratio of the mean value of deoxy-hemoglobin (ctHHbN) at two weeks after the first treatment compared to baseline was statistically significantly lower in patients that achieve a pathologic complete response (pCR) (0.77 ± 0.22) as compared to patients with a non-pCR (1.14 ± 0.24, P < .005). These observations indicate that early changes in DOTBIS images can potentially be used to predict breast cancer response to NAC and may allow a better way to customize therapy to HR+/HER2- patients in order to optimize treatment.
Optical imaging techniques have emerged as a possible alternative to predict pathological complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). Our team developed a so-called diffuse optical tomographic breast imaging system (DOTBIS) which does not require the use of contrast agents or compression and enables imaging of the whole breast volume using low intensity near infrared light capable to measure tissue concentration of total hemoglobin (ctTHb). In this retrospective study, we evaluated 55 stage II-III BC patients in the neoadjuvant setting who received weekly paclitaxel x 12, followed by dose-dense adriamycin/cyclophosphamide every 2 weeks x 4. DOTBIS images were acquired from the patient whole breast volume at 6 different time points: at baseline (TP0); two weeks after the first taxane infusion (TP1); after four infusions of taxane (TP2); at the end of the taxane regimen and before starting AC cycle (TP3); after two AC infusions (TP4); and at the end of NAC and before surgery (TP5). In order to evaluate whether pCR status influences the change of ctTHb over time, we designed a multilevel mixed-effect model. pCR was defined as no invasive tumor cells from the breast and axillary tissue at surgery (ypT0 ypN0). Changes in ctTHb levels compared to baseline (TP0) values were statistically significant different between pCR (n = 20) and non-pCR (n=35) at all time points except at TP1 and at the end of the taxane cycle (TP3).
The aim of this study was to investigate the optical chemotherapy changes induced by neoadjuvant chemotherapy (NAC) in PgR-positive and PgR-negative breast cancer subtypes using a diffuse optical tomographic breast imaging system (DOTBIS). ctTHb reduction in the tumor volume was greater for patients with PgR-negative, a statistically significant difference of 48.91μM, p = .022, which suggest that PgR-negative tumors are generally less resistant to NAC. These observations indicate that PgR negativity may be combined to optically derived biomarkers for predicting pCR during neoadjuvant chemotherapy.
In this retrospective cohort study, we examine the hypothesis that baseline oxygen saturation (SO2%) in contralateral normal tissue can be a quantitative measurement for predicting tumor response to neoadjuvant chemotherapy (NAC). Using our dynamic custom-built dual breast dynamic diffuse optical tomography (DOT) imager, we reconstructed SO2% measurement concentration for 12 stage II or III breast cancer patients. Six patients achieved pCR (RCB-0) and the other half had extensive residual disease (RCB-III). Baseline SO2% in contralateral normal tissue was statistically significantly higher in RCB-III subjects than in pCR (p = 0.025). From ROC analyses, baseline SO2% in contralateral normal breast tissue was able to discriminate pCR from RCB-III patients (AUC 0.889) with sensitivity and specificity of 83%.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.